Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diamminedichloroplatinum
Drug ID BADD_D00643
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 441203
TTD Drug ID D08ZRW
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula Cl2H6N2Pt+2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt+2]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Renal tubular disorder20.05.03.004--Not Available
Retinal pigmentation06.09.03.008--Not Available
Rhinorrhoea22.12.03.021--
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin necrosis23.03.03.011--Not Available
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Tetany15.05.03.013; 14.04.01.005; 05.04.02.003--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.006--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Hypoacusis04.02.01.006--
Retinal toxicity12.03.01.036; 06.09.03.013--Not Available
Lhermitte's sign17.02.06.014--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Loss of proprioception17.02.07.019--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages